Back to Directory
Insulin Lispro
Performance & EnduranceRapid-acting insulin analog, marketed as Humalog, first rapid-acting analog approved.
Key Benefits
- ✓Rapid mealtime coverage
- ✓Fast onset
- ✓Flexible dosing
- ✓Better postprandial control
- ✓First rapid-acting analog
Dosing Information
Dosage Range
Variable
Frequency
With meals
Typical Duration
Lifelong for T1D
Detailed Protocol
Administered subcutaneously or via pump. Dosed with meals based on carbs and glucose. Given 0-15 minutes before eating. Prescription required.
About Insulin Lispro
Insulin lispro (Humalog) is a rapid-acting insulin analog with lysine and proline at positions B28 and B29 reversed. First rapid-acting analog approved. Faster onset than regular human insulin for better mealtime control.
Research Notes
FDA-approved in 1996, first rapid-acting analog. Revolutionized mealtime insulin therapy. Biosimilar versions now available. Standard diabetes care.
Potential Side Effects
- •Hypoglycemia
- •Weight gain
- •Lipodystrophy
- •Injection site reactions
Always consult with a healthcare professional before starting any peptide therapy.